CD8A and neoplasm: In the phase 2 clinical trial of neoadjuvant nivolumab plus relatlimab, an association was found between a higher frequency of CD45-positive cells in the tumor at baseline and the pathological response [27], while in the phase 2/3 trial of this combined immunotherapy in an advanced metastatic setting, the response to treatment was associated with a higher number of CD8-positive T cells positive for PD-1 and positive for ICOS [50].